4SC in $192M Agreement for Japan Rights to Resminostat
By Cormac Sheridan
Friday, April 15, 2011
Setting down a weighty marker for partnering deals elsewhere, 4SC AG is pocketing €6 million (US$8.7 million) up front and could earn another €127 million in milestones, for licensing Japanese rights to its oral pan-histone deacetylase (HDAC) inhibitor resminostat (4SC-201).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.